2400917-55-5 = 913611-97-9 [标题:Reaction Conditions 标题:Creation Of A Ready-To-Use Brexpiprazole Suspension And The Inflammation-Mediated Pharmacokinetics By Intramuscular Administration 作者:Wang,Junji; Liu,Junfeng; Ding,Jingwen; Li,Qin; Zhao,Yuan; Et Al 参考文献:European Journal Of Pharmaceutics And Biopharmaceutics 日期:2023 卷标:189 页码:189-201]
913613-82-8 + 913614-18-3 = 913611-97-9 + 2116542-21-1 + 2094559-58-5 反应条件:1.1 Reagents: Potassium Carbonate Solvents: Ethanol,Water; 15 H,Rt -> Reflux 标题:Industry-Oriented Route Evaluation And Process Optimization For The Preparation Of Brexpiprazole 作者:Chen,Weiming; Suo,Jin; Liu,Yongjian; Xie,Yuanchao; Wu,Mingjun; Et Al 参考文献:Organic Process Research & Development 日期:2019 卷标:23(5) 页码:852-857]
1849603-58-2 + 66490-33-3 = 913611-97-9 反应条件:1.1 Reagents: Sodium Tert-Butoxide Catalysts: Stereoisomer Of [(4S,5S)-1,3-Bis[2,6-Bis(1-Methylethyl)Phenyl]-4,5-Diphenyl-2-Im... Solvents: 1,2-Dimethoxyethane; 16 H,Rt 标题:A Bulky And Electron-Rich N-Heterocyclic Carbene Palladium Complex (Sipr)Ph2Pd(Cin)Cl: Highly Efficient And Versatile For Buchwald-Hartwig Amination Of (Hetero)Aryl Chlorides With (Hetero)Aryl Amines At Room Temperature 作者:Ouyang,Jia-Sheng; Liu,Siqi; Pan,Bendu; Zhang,Yaqi; Liang,Hao; Et Al 参考文献:Acs Catalysis 日期:2021 卷标:11(15) 页码:9252-9261]
203395-59-9 + 1677681-05-8 = 913611-97-9 反应条件:1.1 Reagents: Potassium Carbonate Solvents: Dimethylformamide; 30 Min,Rt1.2 Reagents: Potassium Iodide; 4 H,100 °C; 100 °C -> 0 °C1.3 Reagents: Water; 30 Min,0 °C 标题:Delineating An Alternate Convergent Synthesis Of Brexpiprazole Using Commercial 6,7-Dihydrobenzo[b]Thiophen-4(5H)-One As Precursor To An Efficacious Buchwald-Hartwig Amination Step 作者:Kumar,A. Sravanth; Kandanur,Sai Giridhar Sarma; Sen,Saikat; Oruganti,Srinivas 参考文献:Journal Of Chemical Sciences (Berlin 日期:2018 卷标:130(6) 页码:1-10]
913613-82-8 + 913614-18-3 = 913611-97-9 反应条件:1.1 Reagents: Potassium Carbonate,Potassium Iodide Solvents: Dimethylformamide; Rt -> 70 °C; 10 H,70 °C1.2 Solvents: Water 标题:Identification,Synthesis,And Control Of Process-Related Impurities In The Antipsychotic Drug Substance Brexpiprazole 作者:Tyagi,Rahul; Singh,Harnam; Singh,Jagat; Arora,Himanshu; Yelmeli,Vijayalaxmi; Et Al 参考文献:Organic Process Research & Development 日期:2018 卷标:22(11) 页码:1471-1480]
7-[4-(4-Benzo[b]Thiophen-4-Yl-Piperazin-1-yl)Butoxy]-1H-Quinolin-2-One Hydrochloride置于sodium Hydroxide体系中,用 乙醇,水 作为反应溶剂,化学反应 2.0H,以96.1%的收率获得产物依匹唑派 参考文献: Processes For Preparing Brexpiprazole[fr] Procédés De Préparation De Brexpiprazole 标题: Processes For Preparing Brexpiprazole[fr] Procédés De Préparation De Brexpiprazole 摘要:本公开提供了制备布瑞沙班的方法.本公开还提供了布瑞沙班的纯化方法.本发明的制备和纯化布瑞沙班的方法相比目前已知的方法有显著的改进.在某些实施例中,将公式xi和xii转化为xiii提供了比以前报道的方法更高的选择性,这提供了更高的产量和纯度.本公开披露的改进的布瑞沙班纯化方法提供了具有卓越纯度的布瑞沙班,并且更适合工业生产.
专利号:US-2023271983-A1 优先权日:2020-07-29 标题 :Functionalized isonitriles and products, preparation and uses thereof 发明人:SOTELO PÉREZ EDDY; AZUAJE GUERRERO JHONNY ALBERTO; MAJELLARO MARIA 权利人:UNIV SANTIAGO COMPOSTELA 摘要:The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.
专利号:WO-2025118034-A1 优先权日:2023-12-06 标题 :Compounds active at the serotonergic 5-ht2a receptor 发明人:JORGENSON WILLIAM; TAN JINLONG; WHISH LACHLAN; BANISTER SAMUEL 权利人:Psylo Pty Ltd 摘要:The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
专利号:US-12415804-B2 优先权日:2023-06-28 标题 :Compounds for activating a serotonin receptor 发明人:BANISTER SAMUEL; JORGENSEN WILLIAM; TAN JINLONG; WHISH LACHLAN 权利人:Psylo Pty Ltd 摘要:The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
专利号:US-12428380-B2 优先权日:2023-06-28 标 题 :Compounds 发明人:BANISTER SAMUEL; JORGENSEN WILLIAM; TAN JINLONG; WHISH LACHLAN 权利人:Psylo Pty Ltd 摘要:The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
专利号:US-2025101038-A1 优先权日:2021-12-24 标 题 :Compounds 发明人:BANISTER SAMUEL; JORGENSEN WILLIAM; TAN JINLONG 权利人:Psylo Pty Ltd 摘要:The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
专利号:US-2025163044-A1 优先权日:2021-12-24 标 题:Compounds 发明人:BANISTER SAMUEL; JORGENSEN WILLAM; TAN JINLONG 权利人:Psylo Pty Ltd 摘要:The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
1: Jackowiak EM, Chou KL. Severe parkinsonism caused by brexpiprazole: A case report. Parkinsonism Relat Disord. 2019 Nov 13;69:138-139. doi: 10.1016/j.parkreldis.2019.11.013. [Epub ahead of print] doi: 10.1254/fpj.154.275. Japanese. doi: 10.1097/JCP.0000000000001127. doi: 10.1016/j.ajp.2019.10.016. [Epub ahead of print] doi: 10.1097/JCP.0000000000001113. Available from http://www.ncbi.nlm.nih.gov/books/NBK548464/ pii: 18m12680. doi: 10.4088/JCP.18m12680. doi: 10.21873/anticanres.13667. doi: 10.1080/14656566.2019.1654457. Epub 2019 Aug 20. doi: 10.1080/14737175.2019.1653759. Epub 2019 Aug 14. doi: 10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. doi: 10.1093/ijnp/pyz040. 17: Thase ME, Zhang P, Weiss C, Meehan SR, Hobart M. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother. 2019 Oct;20(15):1907-1916. doi: 10.1080/14656566.2019.1638913. Epub 2019 Jul 10. Review. pii: E947. doi: 10.3390/cancers11070947. 19: Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008. Epub 2019 Jun 27. Review. doi: 10.18632/oncotarget.26949. eCollection 2019 May 28.
合成参考文献
参考文献:10.1007/s00213-017-4543-7 摘要:Milienne-Petiot M, Geyer MA, Arnt J, Young JW. Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017–28. 参考文献:10.1038/s41386-019-0451-3 摘要:Thase ME, Stanford AD, Memisoglu A, Martin W, Claxton A, Bodkin JA, Trivedi MH, Fava M, Yu M, Pathak S. Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. Neuropsychopharmacology. 2019 Jun 29;44(13):2268–76. doi: 10.1038/s41386-019-0451-3. 参考文献:10.1016/j.euroneuro.2019.06.008 摘要:Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):971–85. doi: 10.1016/j.euroneuro.2019.06.008.